A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Glucagon (Primary)
- Indications Hypoglycaemia
- Focus Registrational; Therapeutic Use
- Sponsors AMG Medical; Locemia Solutions
- 22 Mar 2017 Status changed from active, no longer recruiting to completed.
- 07 Mar 2016 Planned End Date changed from 1 Nov 2015 to 1 Apr 2016 according to the ClinicalTrials.gov record
- 10 Aug 2015 Planned End Date changed from 1 Sep 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov.